Rationale Surrounding Luspatercept as Potential First-Line Treatment Option for Patients With MDS

Opinion
Video

Dr Jamie L. Koprivnikar discusses the rationale surrounding luspatercept as a potential first-line treatment option for patients with myelodysplastic syndrome, and if it would have been an appropriate therapy for the patient in the presented case study.

Related Videos
Brooke Peters, PharmD, BCOP, a clinical pharmacist
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Expert on DLBCL
Related Content